Effect of Hand Holding on Pain and Anxiety
Effect of Hand Holding on Reducing Intramuscular Injection-Induced Pain and Anxiety: A Randomized Controlled Study
1 other identifier
interventional
104
1 country
1
Brief Summary
It was aimed to examine the effect of the hand holding method applied during intramuscular injection on pain and anxiety.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2024
CompletedFirst Posted
Study publicly available on registry
May 16, 2024
CompletedStudy Start
First participant enrolled
July 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 10, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 10, 2024
CompletedAugust 26, 2025
August 1, 2025
2 months
May 12, 2024
August 19, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Numerical Pain Scale
A score of "0" indicated the lowest pain, and a score of "10" indicated the highest pain.
It will be filled within 1 minute after the intramuscular injection is completed.
Secondary Outcomes (1)
State Anxiety Scale
It will be filled immediately before the intramuscular injection and within 1 minute after the procedure is completed.
Study Arms (2)
Hand Holding Group
EXPERIMENTALIn the experimental group, hand holding will be done by the researcher, and intramuscular injection will be done by the clinical nurse. All intramuscular injections will be performed by a single nurse and the ventrogluteal region will be used as the injection site. Patients will first fill out the Voluntary Information and Consent Form, and then the Descriptive Characteristics Form and State Anxiety Scale. After the injection site is evaluated, the researcher will hold the patient's hand, the nurse will enter the tissue at a 90-degree angle and administer the drug slowly (1 ml/10 seconds). After removing the needle from the tissue, the nurse will apply pressure with dry cotton, and then the researcher will stop holding the patient's hand. After the procedure, the Numerical Pain Scale and State Anxiety Scale will be filled in within 1 minute.
Control Group
NO INTERVENTIONIn the control group, intramuscular injection will be performed by the clinic nurse. All intramuscular injections will be performed by a single nurse and the ventrogluteal region will be used as the injection site. Patients will first fill out the Voluntary Information and Consent Form, and then the Descriptive Characteristics Form and State Anxiety Scale. After the injection site is assessed, the nurse will enter the tissue at a 90-degree angle and administer the medication slowly (1 ml/10 seconds). After removing the needle from the tissue, the nurse will apply pressure with dry cotton. After the procedure, the Numerical Pain Scale and State Anxiety Scale will be filled in within 1 minute.
Interventions
During the intramuscular injection, the aim is to draw the patients' attention elsewhere by holding their hand.
Eligibility Criteria
You may qualify if:
- Having vitamin B 12 1000 mcg/ml (1 ml ampoule) intramuscular treatment,
- Being literate,
- Are between the ages of 18-65,
- No visual, hearing, sensory or motor loss or cognitive impairment,
- Not using centrally or peripherally acting analgesics or sedatives,
- There is no scar tissue, incision, lipodystrophy or signs of infection on the skin of the injection area,
- Having a body mass index between 18.5 and 29.5,
- Injected into the ventrogluteal area,
- Individuals who agree to participate in the research will be included.
You may not qualify if:
- Those with chronic pain,
- Having a psychiatric disorder,
- Foreign nationals,
- Patients with contact-communicable diseases will be excluded from the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Necmettin Erbakan University
Konya, Meram, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Serpil SU
Necmettin Erbakan University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- Double (Participant, Outcomes Assessor) The patients will be informed about the study and their consent will be obtained without explaining which group they are in. Since the researcher manages the implementation process of the study, researcher blinding cannot be done. In addition, it will be ensured that the researcher learns which group the patients are in after the patients accept to participate in the study. Thus, the internal validity of the research will be ensured. At the same time, blind technique will be applied in terms of statistical analysis in the research. The data will be recorded on the computer by the researcher without using the expression of experimental and control groups, and data analysis will be done by another statistician other than the person who made the randomization.
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professors
Study Record Dates
First Submitted
May 12, 2024
First Posted
May 16, 2024
Study Start
July 20, 2024
Primary Completion
September 10, 2024
Study Completion
September 10, 2024
Last Updated
August 26, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share